AKA. V. Koryakin

A. V. Koryakin

*This is an algorithmically generated author record based on publicly available information.

A. V. Koryakin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retrospective Analysis of MRI Data in Patients Undergoing Fusion Biopsy of the Prostate

    by A. I. Gromov, A. V. Koryakin, A. D. Kaprin, B. B. Alekseev, A. V. Sivkov, I. S. Tolstov

    To investigate the causes of low diagnostic accuracy of MRI criteria for prostate cancer by correlation with histopathological findings from MRI-targeted fusion biopsy. Materials and methods. A retrospective analysis of prostate MRI data was performed in 38 patients who subsequently underwent MRI-targeted fusion biopsy. All imaging studies were independently reviewed by a radiologist with 7 years of experience in prostate imaging. Identified suspicious lesions were correlated with histopathological findings from corresponding prostate biopsy samples. The causes of discordant results were systematically analyzed and categorized. Results. The MRI studies identified 54 MRI-positive lesions that subsequently underwent fusion biopsy. Among these, 34 cases demonstrated false-positive MRI findings attributed to the following causes: localized inflammation exhibiting T2-weighted hypointensity, restricted diffusion, and early contrast enhancement (16 cases, including wedge-shaped lesions); encapsulated hyperplastic nodules (7 cases); and minimal lesion size (3 cases). Two cases resulted from overinterpretation of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI data. Systematic biopsy revealed adenocarcinoma in 24 tissue samples obtained from areas not identified as suspicious on MRI (false-negative results). Retrospective analysis of MRI findings allowed detection of subtle abnormalities in only one of these cases. The MRI demonstrated a sensitivity of 45% and positive predictive value of 37%. Conclusion. The study results revealed substantial subjectivity in MRI data interpretation for prostate cancer diagnosis. Overdiagnosis of tumorous changes was significant, with false-positive rates of 55% in the peripheral zone (PZ) and 72% in the transition zone (TZ). The highest proportion of errors (76%) occurred in PI-RADS category 3 lesions, where 26 out of 34 false-positive findings were associated with this group. The primary cause of misdiagnosis (32% of cases) was morphologic changes caused by diffuse or localized inflammation mimicking tumor features: hypointensity on T2-weighted imaging (T2WI), restricted diffusion, and early enhancement on dynamic contrast-enhanced (DCE) MRI. In 21% of TZ cases, errors were related to insufficient attention to the complete encapsulation sign of suspicious nodules, which can be confirmed through sequential analysis of T2WI on adjacent slices. An additional 15% of false-positive results in the PZ occurred due to underestimation of wedge-shaped lesion morphology, a key differential diagnostic feature. These findings highlight the need for standardized MRI evaluation criteria, detailed analysis of lesion characteristics, and incorporation of clinical inflammation data to reduce overdiagnosis.


  • Open Access

    Comparison of the results of surgical treatment using various types of access in patients with prostate cancer: oncological, functional, and financial effectiveness

    by K. M. Nyushko, V. M. Perepukhov, B. Ya. Alekseev, O. I. Apolikhin, A. D. Kaprin, A. V. Sivkov, A. V. Koryakin, V. P. Aleshin

    Prostate cancer is a very important problem in modern urologic oncology. The reason for this is a steady increase of morbidity and mortality in Russia and worldwide. Surgical treatment and hormonal/radiation therapy combination are the golden standard of radical therapy in patients with local and locally advanced prostate cancer. Vast experience has been accumulated worldwide in radical prostatectomy using various types of access: open retropubic, perineal, laparoscopic, and robot-assisted. Many studies focused on finding advantages of using minimally invasive access for this surgery, but the results are quite contradictory.The article presents a systematic review of literature data, evaluation of the effectiveness of each access in radical prostatectomy in patients with prostate cancer.

  • Open Access

    Transperineal fusion prostate biopsy. Diagnostic value in comparison with a standard biopsy.

    by R.A. Romanov, Russia Moscow, A.V. Koryakin, I.S. Tolstov, V.I. Kirpatovskiy, B.YA. Alekseev

    Introduction. A significant improvement in the quality of prostate imaging by magnetic resonance (MRI), as well as the possibility of combining MRI and ultrasound images (fusion technology) for biopsy, open up new possibilities for the diagnosis of prostate cancer. The arsenal of methods of treating prostate cancer includes active surveillance and focal therapy for patients with low risk disease. That raises the question of improving the accuracy of diagnosis of tumor volume, stage and differentiation, which will largely determine the tactics of patient management. The aim of our work was to determine the diagnostic effectiveness of targeted MRI-assisted fusion biopsy of the prostate in comparison with standard biopsy. Materials and methods. We analyzed data of 356 patients who underwent tranperineal fusion biopsy. The age of the patients ranged from 48 to 72 years with an average value of 68.2 ± 2.1 years. The selection criteria for the study were an increase in the level of PSA (345 patients) – the range from 4 to 44.5 ng/ml (on average 6.02±0.21) or the detection of tumor-suspicious areas during finger rectal examination or transrectal ultrasound examination (TRUS) of the prostate gland (41 patients). Further methods of examination included multiparametric magnetic resonance imaging (MRI) and subsequent transperineal fusion biopsy in combination with standart biopsy. Results. In our study, the detection rate of prostate cancer was (82.6%) – the diagnosis was confirmed in 294 out of 356 examined patients. At the same time, with an increase in the PI-RADS gradation, the frequency of histological confirmation of cancer increased: 62.4% for PI-RADS 3 lesions, 89.6% for 4 and 96.7% for PI-RADS 5. Targeted biopsies confirmed the presence of prostate cancer in 246 cases out of 356 patients (69.1%). In relation to all cases of cancer detection, the proportion of positive targeted biopsies was 83.7%. Conclusion. Targeted MRI-assisted fusion biopsy allows detecting prostate cancer in 69.1%, but when supplemented with a polyfocal biopsy at standard points, the diagnostic accuracy increases to 82.6%. Thus, the data obtained allow us to conclude that based on the examination of patients with suspected prostate cancer using mpMRI with targeted fusion biopsy, supplemented by polyfocal biopsies at standard points, it is possible to determine the localization, extent and degree of malignancy of the tumor with a high degree of certainty.


  • Open Access

    Brachytherapy for prostate cancer and immune response.

    by A.V. Sivkov, N. Lopatkin Research Institute of urology and Interventional Radiology – branch of the National Medical Research Radiological Centre of Ministry of health of Russian Federation, V.N. Sinyukhin, A.V. Koryakin, Russia Moscow

    Introduction. Information about the brachytherapy-induced immune reactions, which can be used for therapeutic purposes, is of great clinical value. Materials and methods. When preparing a review of the literature on the problem of the effect of brachytherap (BT) on immunity in prostate cancer (PCa), the following bibliographic databases were used: PubMed, Science Direct, Scientific Electronic Library of Russia (eLibrary). The search was conducted on the following keywords: «cancer», «prostate cancer», «brachytherapy», «immunity», «immunotherapy». In total, 6 sources were found that were directly related to the effect of BT on immunity in prostate cancer. Results. Clinical data shows that both low-dose and high-dose prostate cancer brachytherapy (BT) cause a systemic immune response. The authors explain the observed increase in the number of serum leukocytes by the induction of an inflammatory reaction in response to tumor irradiation, and the decrease in the number of B cells by the movement of antigen-recognizing B cells from the bloodstream to the irradiation site. In addition, after BT, an increase in the number of activated T-lymphocytes was demonstrated, while the number of myeloid suppressor cells significantly decreased. It has been suggested that a decrease in this indicator can activate T cells: the number of naive CD4+ and CD8+ T lymphocytes significantly increased after local administration of radioactive sources, with a simultaneous decrease in the number of CD4+ and CD8+ memory T cells. The latter may indicate that local radiotherapy stimulates the activation of the thymus and the release of naive T-lymphocytes into the bloodstream, during the migration of memory cells from the bloodstream to the prostate. The described effects reflect the process of «turning on» T-cell immunity after BT. Researchers believe that an increase in the number of activated T-lymphocytes contributes to the activation of antitumor immunity, long-term remission and reduces the likelihood of recurrence of prostate cancer. High-dose BT of localized prostate cancer, as well as probably low-dose BT, cause the transformation of the immunogenic properties of the tumor and lead to pronounced polyclonal infiltration of the prostate, mainly by T cells, which occurs under the control of a large number of «control points». The occurrence of immune cells infiltrates and changes in the signal transmission system between them after BT are reflected by a change in the type of «inflammatory signature of the tumor» (TIS) from «cold» to «hot». After irradiation in the tumor area the number of PD-L1 macrophages usually increases, which is regarded as a marker of the tumor response to the therapy. It is believed that if BT causes an increase in PD1+ expression, and use of checkpoint inhibitors to these patients can give a good therapeutic effect. Conclusion. The available data indicate that BT primes the systemic immune response, leads to activation of T-cell immunity and, as a consequence, antitumor immunity. All this opens up prospects for the development of prostate cancer combined treatment methods, using BT and immunotherapy.

  • Open Access

    Utility of fusion biopsy for choosing prostate cancer patients eligible for focal therapy

    by R. A. Romanov, A. V. Koryakin, V. I. Kirpatovskiy, B. Ya. Alekseev

    Background. Focal therapies for prostate cancer (PCa) can preserve the quality of life; however, their application is limited by lack of confidence in identifying the exact tumor location.Aim. To evaluate the utility of fusion biopsy for choosing PCa patients eligible for focal therapy with subsequent confirmation by the analysis of radical prostatectomy (RPE) samples.Materials and methods. This study included 122 patients with histologically verified stage Т1–2N0M0 PCa treated in N.A. Lopatkin Research Institute of Urology and Interventional Radiology, a branch of the National Medical Research Radiology Center. Their mean age was 65.2 ± 6.8 years. All patients underwent multiparametric magnetic resonance imaging and fusion biopsy (samples were collected from targeted areas in combination with a standard biopsy), followed by histological examination of biopsy samples and mapping of the affected areas. Twenty-eight patient underwent RPE.Results. Study participants were distributed as follows by their Prostate Imaging Reporting and Data System (PI-RADS) score: 5 points in 23 patients (18.9 %), 4 points in 57 patients (46.7 %), and 3 points in 42 patients (34.4 %). Targeted biopsy revealed cancer in 105 out of 122 patients (86.1 %) in at least one sample. Seventeen targeted biopsy samples were negative. The majority of patients had ISUP (International Society of Urological Pathology) grade 1 (n = 57; 46.8 %) and grade 2 (n = 33; 27.0 %) tumors. Comparison of biopsy findings and results of pathological examination of the removed prostate demonstrated significant discrepancies in the distribution of cases by their ISUP grades. Almost half of the patients (46.8 %) were diagnosed with ISUP grade 1 tumors after biopsy, while the assessment of RPE specimen demonstrated ISUP grade 1 tumors only in 21.4 % of patients. ISUP grade 3 tumors were diagnosed in 16.4 % and 35.7 % of patients using biopsy- and RPE-derived specimens, respectively. The proportions of ISUP grade 2, 4, and 5 tumors were similar with both methods. In 27 out of 28 cases, examination of biopsy- and RPE-derived specimens demonstrated complete agreement in terms of tumor location. Importantly, this study included only patients with histologically confirmed PCa; so we didn’t evaluate the effectiveness of biopsy for cancer diagnosis. Focal therapy could have been considered in 22 out of 28 patients (78.6 %) who underwent RPE. This proportion of focal therapy-eligible patients is almost equal to that identified by fusion biopsy (75.4 %).Conclusion. Multiparametric magnetic resonance imaging in combination with targeted and multifocal prostate biopsy allow precise identification of candidates eligible for focal therapy with a relatively low risk of an erroneous conclusion.

  • Open Access

    Brachytherapy of localized prostate cancer by domestic sources I-125: own experience of the National Medical Research Center of Radiology

    by Medical Radiological Research Center named after A.F. Tsyb - branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, Biryukov V.A. Biryukov, Russia Moscow, V.A. Polyakov, A.V. Chernichenko, A.V. Koryakin, V.F. Stepanenko, O.G. Lepilina, S.A. Artamonov, A.S. Bolonkin, et al.

    Introduction. One of the effective and minimally invasive methods prostate cancer treatment is interstitial radiation therapy, the essence of which is the implantation of radioactive microsources into the tumor tissue. Brachytherapy of prostate cancer is performed in more than 20 clinics in the Russian Federation using mainly foreign microsources, but their high cost does not allow increasing the number of operations and opening new brachytherapy departments in the Russian Federation. Based on the model of foreign microsources such as seed No. 6711 (Nicomed Amersham), a technology for the manufacture of microsources with iodine-125 (IPPE SEED) has been developed at the State Research Center of the Russian Federation - IPPE, as well as a pilot production facility with a capacity of up to 50 thousand items per year. Materials and methods. In order to assess the safety of microsources for medical personnel during brachytherapy, local dosimetric control was carried out. As part of a clinical study in 2015, 36 patients with stage T1 – T2 prostate cancer underwent low-power brachytherapy using domestic microsources. Results. The obtained values of absorbed doses do not differ within the limits of measurement errors from the values of doses determined during the operation with foreign microsources under similar conditions. It follows from the data obtained that even the maximum values of the measured local absorbed doses do not pose a radiation hazard when using IPPE SEED microsources for brachytherapy. Among the treated patients, adverse reactions were in the expected manifestations of grade 1 dysuria according to the RTOG / EORTC classification. No gastrointestinal toxicity has been reported. Patient monitoring was continued in order to obtain long-term results of treatment. PSA disease-free survival at 5-year follow-up was 94.4%. Discussion. Clinical trials of Russian medical devices have demonstrated their safety for patients and medical personnel, which was proved by conducting dosimetry control during the procedure itself, as well as during examination of patients after brachytherapy. The effectiveness of Russian microsources I-125 during low-power brachytherapy is demonstrated by a decrease in PSA level from baseline by 87% at a follow-up period of 6 months. The disease-free survival rate for 5 years was 94.4%. The absence of significant radiation reactions both in the early and in the late postoperative period is important. The low cost of microsources produced by JSC «SSC RF – IPPE» relative to foreign analogs makes it possible to increase the number of operations performed annually, and also gives prospects for opening new divisions performing interstitial radiation therapy operations. Conclusions. Russian microsources «IPPE SEED» have successfully passed clinical trials, during which their effectiveness and safety were proved. The study also demonstrated high rates of relapse-free survival and a low level of adverse reactions in treated patients.


  • Open Access

    MRI-TRUS fusion biopsy in diagnostics of prostate cancer

    by P.A. Hertzen Moscow scientific research oncology institute - branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia, R.A. Romanov, Russia Moscow, A.V. Koryakin, A.V. Sivkov, B.Ya. Alekseev, V.I. Kirpatovskiy, O.I. Apolikhin, A.D. Kaprin

    Introduction. Significant improvement in the quality of visualization of the prostate using magnetic resonance imaging (MRI), as well as the development of technologies for virtual combination of MRI and ultrasound images opens new horizons in the diagnosis of prostate cancer. The introduction of the PI-RADS system has allowed the standardization of MRI findings, and the development of fusion biopsy systems seeks to make diagnostics more accurate and less operator-dependent. Materials and methods. In this literature review, we evaluate the effectiveness of various biopsy approaches and discuss the prospects for targeted biopsies. The search for publications was carried out in the databases PubMed, e-library, Web of Scince et al. For citation, 55 literature sources were selected that met the search criteria for the keywords, «prostate cancer», «biopsy», «MRI», «TRUS», «fusion». Results. Diagnosis of prostate cancer using MRI. Modern technologies for radiological diagnosis of prostate cancer using magnetic resonance imaging (MRI) are based on the standardized PI-RADS protocol, using different modes (T2, diffusion-weighted images and contrast enhancement), which provides the best visualization of tumor-suspicious nodes in the prostate gland, allowing determination of lesion localization and size for subsequent targeted biopsy. Options for performing a prostate biopsy to diagnose prostate cancer. A description of the methods and effectiveness of transrectal and transperineal biopsy under ultrasound guidance is carried out - due to the fact that ultrasound diagnostics of prostate cancer has a rather low sensitivity due to small differences in the ultrasound structure of normal and tumor tissue of the prostate, an extended template biopsy technique was proposed, which involves puncture of the prostate through a special lattice. It also describes the technology of fusion biopsy and also provides literature data comparing the diagnostic accuracy of standard TRUS and fusion prostate biopsy, as well as the importance of transrectal / transperineal access. Questions for further study. Given the desire to reduce the number of biopsies while maintaining or even increasing the accuracy of diagnosing prostate cancer, data from studies investigating the feasibility of combining polyfocal (non-targeted) and targeted (targeted) biopsies are presented. Conclusion. The existing methods of non-targeted biopsy (polyfocal, saturation, template) and targeted (fusion biopsy) have their advantages and disadvantages, which currently do not allow making certain recommendations for their use, but a significant number of authors prefer MRI-as sisted, fusion -biopsy.


  • Genitourinary system and COVID-19: some aspects

    by A.V. Sivkov, N.A. Lopatkin Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation, A.V. Koryakin, A.A. Sinyagin, O.I. Apolikhin, A.D. Kaprin, National Medical Research Centre of Radiology of Ministry of health of Russian Federation


  • Prediction of biochemical-free survival for patients with prostate cancer after 125I brachytherapy.

    by N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation, A.V. Koryakin, A.V. Sivkov, V.N. Oshchepkov, Tyumen State Medical University Russian Federation, D.A. Roshchin, B.Ya. Alekseev, National Medical Research Centre of Radiologyof Ministry of health of Russian Federation, O.I. Apolikhin, A.D. Kaprin, et al.